ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 3740.2 | 3603.3 | 3371.1 |
| Other income | 152.8 | 200.1 | 136.5 |
| Total income | 3892.9 | 3803.4 | 3507.6 |
| Profit before exceptional items & tax | 772.0 | 557.8 | 758.1 |
| Exceptional items | 0.0 | -135.0 | 12.9 |
| Profit before tax | 772.0 | 422.9 | 771.0 |
| Net profit | 521.0 | 251.1 | 667.9 |
| Operating margin | 19.8% | 11.1% | 22.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -22.00% |
|---|---|
| Net profit, quarter on quarter | +107.50% |
| Revenue, year on year | +10.90% |
| Operating profit, year on year | -0.40% |
| Operating profit, quarter on quarter | +73.10% |
NSE results filing, NSE: ALKEM. Figures extracted from the filing.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,334.50
- Market cap
- ₹63,782 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 29.6×Sector 43.8×
- Promoter holding
- 49.70%+0.00% QoQ
- FII holding
- 10.32%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Merger & Restructuring Worth ₹9.56 Cr
Alkem incorporated a Saudi Arabian joint venture subsidiary, Alkem Pharma Company LLC, on 8 November 2026. It holds 51% after subscribing SAR 38.25 lakh, about ₹9.56 Crore.
- Value
- ₹9.56 Cr
Alkem Laboratories Board Meeting Date
Alkem Laboratories has scheduled its Board meeting for 12 Nov 2026 to consider Q2 and H1 FY27 unaudited results. No financial figures are disclosed in this advance notice.
Alkem Laboratories Management Change
Alkem Laboratories appointed Dr. Amrut Naik as CEO effective November 11, 2026. The Board designated him as Key Managerial Personnel at its November 3 meeting.
Alkem Laboratories Business Update
Alkem informed the exchange that US FDA completed inspection of its Mandva API facility with no Form 483 observations. The clean result confirms regulatory compliance.
Alkem Laboratories Legal & Regulatory
Alkem Laboratories has initiated a forensic audit by Grant Thornton Bharat LLP following alleged misappropriation of funds by a former employee.
Alkem Laboratories Other Announcement
Alkem Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements. This document details the company's equity structure.